Breaking News
May 23, 2018 - Medical students take to the streets to learn about real world problems at the root of poor health
May 23, 2018 - New efforts to curb high blood pressure in Asia
May 23, 2018 - Malaria-causing parasite seeks refuge inside the liver to replicate and survive
May 23, 2018 - Slower rates of stimulation may be more effective in brain therapy, suggests research
May 23, 2018 - Study finds connection between one partner’s BMI and other spouse’s risk of developing diabetes
May 23, 2018 - Mapping the Genes Responsible for Pluripotency
May 23, 2018 - FDA Alert: Homeopathic Teething Drops, Nausea Drops, Intestinal Colic Drops, Stomach Calm, Expectorant Cough Syrup, Silver-Zinc Throat Spray, and Argentum Elixir by MBI Distributing: Recall
May 23, 2018 - Genetic fixer-uppers may predict bladder cancer prognosis
May 23, 2018 - Investigational technology could increase donor organ supply for lung transplants
May 23, 2018 - Prediabetic patients with OSA could lower their resting heart rates by using CPAP
May 23, 2018 - Schizophrenics’ blood samples feature genetic material from more types of microorganisms
May 23, 2018 - Subtle hearing deficits can change the brains of young people
May 23, 2018 - New study shows increased rates of hospitalization for suicide among youths
May 23, 2018 - Proportion of Drug-Intoxicated Organ Donors on the Rise in U.S.
May 23, 2018 - Using virtual biopsies to improve melanoma detection
May 23, 2018 - Compassion meditation training may increase brain’s resilience to suffering of other people
May 23, 2018 - New AAD PSA uses social media imagery to highlight tanning hazards
May 23, 2018 - Medicaid expansion linked to reduction in ICU utilization
May 23, 2018 - Proteins moderating nicotine dependence may help fat cells burn energy
May 23, 2018 - Researchers identify mechanisms that regulate mammary gland development
May 23, 2018 - ‘Low-Alcohol’ Booze Labels May Backfire
May 23, 2018 - New research shows that children with autism are able to create imaginary friends
May 23, 2018 - New technology could make prosthetic use more intuitive and reliable
May 23, 2018 - HU researchers explore how simulated microgravity affects gene expression, muscle cell differentiation
May 23, 2018 - Researchers develop injectable bandage to stop fatal blood loss, activate wound healing
May 23, 2018 - Exercising for 4-5 days per week is needed to keep the heart young
May 23, 2018 - Porvair Sciences offers wide range of reagent reservoirs for use with automated liquid handling systems
May 23, 2018 - New study unravels secrets of HIV’s persistence
May 23, 2018 - IDF launches initiative to improve health services for displaced people with diabetes
May 23, 2018 - Maintaining healthy weight between early adulthood and middle age could help avoid diabetes
May 23, 2018 - DNA vaccine shows promise for colorectal cancer
May 23, 2018 - Abnormal brain connections seen in preschoolers with autism
May 23, 2018 - Study finds increase in number of calls to US Poison Control Centers about ADHD medication exposures
May 23, 2018 - Yoghurt before a meal packed with health benefits
May 23, 2018 - New tool predicts the lifetime risk of Alzheimer’s
May 23, 2018 - Scientists reveal mechanisms that may help preterm infants extend nephron development window
May 23, 2018 - Unnecessary antibiotic use for asthma exacerbations linked to increased hospital stays, costs
May 23, 2018 - Quitting cigarettes linked to better lung health than long-term light smoking
May 23, 2018 - Researchers shed light on how androgen deprivation therapy increases risk for cardiovascular mortality
May 23, 2018 - Ingesting blue dye tablet during colonoscopy aids in detecting difficult-to-see polyps
May 23, 2018 - Patients with low-back pain benefit from early physical therapy
May 23, 2018 - Researchers discover link between tuberculosis and Parkinson’s disease
May 23, 2018 - FDA Approves Doptelet (avatrombopag) for Chronic Liver Disease Patients with Thrombocytopenia who are Undergoing a Medical Procedure
May 23, 2018 - Is knee pain linked to depression?
May 23, 2018 - Research team uncovers new information that more accurately explains formation of tumors
May 23, 2018 - Brain stimulation shows promise in treating obesity by reducing food cravings
May 23, 2018 - Mediterranean diet may protect people from negative effects of air pollution
May 23, 2018 - Researcher aims to develop virtual biopsy tool for early melanoma detection
May 23, 2018 - Medical centers more willing to perform lung transplants for severe alcoholic hepatitis patients
May 23, 2018 - The brain may tune to social learning even at rest, finds study
May 23, 2018 - Eczema drug alleviates asthma symptoms and improves lung function
May 23, 2018 - Researchers to test two-pronged approach in humans to treat advanced colorectal cancer
May 23, 2018 - FDA Alert: Juluca, Tivicay, Triumeq (dolutegravir): FDA to Evaluate
May 23, 2018 - Neuroscientists say daily ibuprofen can prevent Alzheimer’s disease
May 23, 2018 - Scientists decipher workings of little-understood bacterial riboswitch
May 23, 2018 - Investigational drug offers hope of relief for celiac disease patients exposed to gluten
May 23, 2018 - PCI along with prescribed drugs better than medication alone for treating for people with heart disease
May 23, 2018 - ToolGen’s CRISPR/Cas9 gene editing platform improves T-cell anti-tumor activity in mouse model
May 22, 2018 - FDA approves new drug to treat thrombocytopenia in adults with chronic liver disease
May 22, 2018 - CSIRO study urges Australians to avoid junk protein foods for healthy weight loss
May 22, 2018 - Breath Test Shows Promise for Diagnosis of Esophagogastric CA
May 22, 2018 - Common class of drugs linked to dementia even when taken 20 years before diagnosis
May 22, 2018 - Optimal Biomarker Frequency for Biosensors
May 22, 2018 - Ethics of conducting clinical research during public health emergencies
May 22, 2018 - FDA Approves Aimovig (erenumab), The First Drug Aimed at Preventing Migraines
May 22, 2018 - Warning labels on alcohol containers highly deficient, new research shows
May 22, 2018 - Doctors publish comprehensive proposal to ensure universal access to safe, affordable medications
May 22, 2018 - When is insurance not really insurance? When you need pricey dental care.
May 22, 2018 - Thyroid tumors may be more susceptible to precisely targeted radiation treatment, suggests study
May 22, 2018 - Researchers uncover clues to early lung transplant failure
May 22, 2018 - Coagulation Factor Tests: MedlinePlus Lab Test Information
May 22, 2018 - Booze ads cause risky drinking in young people
May 22, 2018 - Are you and your primary care doc ready to talk about your DNA?
May 22, 2018 - UCI research team uncovers new unexpected mode of neurotransmitter-based communication
May 22, 2018 - Researcher develops nanoparticle-based tags to detect viruses and cancer with high sensitivity
May 22, 2018 - Researchers highlight need for transgender-inclusive healthcare providers
May 22, 2018 - Celgene to share new and updated data around novel hematological therapies
May 22, 2018 - Scientists identify cell types underlying schizophrenia
May 22, 2018 - ACR urges legislative action on access and cost barriers in rheumatologic care
May 22, 2018 - Study examines link between nicotine dependence and likelihood to quit smoking after lung cancer screening
One class of diabetes drug not associated with reduced risk of death

One class of diabetes drug not associated with reduced risk of death

image_pdfDownload PDFimage_print

One class of drug used to treat type 2 diabetes may not reduce the risk of death when compared with placebo, suggests new findings.

The research, led by scientists from Imperial College London and published in the Journal of the American Medical Association, studied three types of diabetes treatment: sodium-glucose cotransporter 2 (SGLT-2) inhibitors, glucagon-like peptide 1 (GLP-1) agonists, and dipeptidyl peptidase 4 (DPP-4) inhibitors. Previous studies suggest these treatments are currently prescribed to at least one in three people with type 2 diabetes.

The team investigated whether these drugs were associated with a lower mortality risk, and conducted a network meta-analysis of 236 trials comparing all the drugs against each other, a placebo, or no treatment at all, and involving 176, 310 patients.

All the drugs lower blood sugar levels but the results revealed that while two of the drugs reduced the risk of death when compared with a placebo, one did not.

The results revealed that SGLT-2 inhibitor drugs were associated with a 20 per cent reduction in risk of death, compared to patients taking an inactive placebo pill, or people taking no medication at all.

The class of GLP-1 agonist drugs meanwhile reduced risk of death by 18 per cent.

However the DPP-4 inhibitor drugs were not associated with a reduced risk of mortality compared to people taking placebo or no treatment at all. Furthermore, SGLT-2 inhibitor drugs and GLP-1 agonist drugs reduced the risk of death compared with DPP-4 inhibitor drugs. There was no significant difference between the SGLT-2 inhibitor and GLP-1 agonist drugs.

Dr Sean Zheng, lead author of the study from National Heart and Lung Institute at Imperial, said: “Type 2 diabetes has become a global epidemic, with more cases than ever before. The three drug classes assessed here are being increasingly prescribed, yet until now there have been no clinical trials studying how these drugs compare to each other, and which type of drug could be the best option for patients.”

Type 2 diabetes is thought to affect 2.8 million people in the UK, and 422 million people worldwide. The condition causes levels of sugar in the blood to become too high, usually because of a lack of insulin – the hormone that mops up blood sugar.

Treatments include diet and exercise, but most people also need medication to control blood sugar. The most commonly prescribed drug is called metformin, but if this doesn’t work, or triggers side effects, patients are usually offered other drugs. The three most recent drugs that have been developed are the SGLT-2 inhibitors, GLP-1 agonists and DPP-4 inhibitors. These work in slightly different ways: SGLT-2 inhibitors increase the amount of sugar excreted by the body, while GLP-1 agonists and DPP-4 inhibitors increase natural insulin levels.

But although these drugs all lower blood sugar, doctors were unclear if one was more effective than another, explained Dr Zheng: “Patients with type 2 diabetes are at higher risk of dying from heart attacks or strokes, so we wanted to investigate which of these three treatments are most efficient at preventing death and cardiovascular diseases. Our hope is that in the crowded market that is diabetes medications, patients and their doctors have the necessary information to allow them to make informed decisions about long-term treatment strategies.”

The team assessed all randomised-controlled trials – the gold-standard trial that randomly assigns patients to a drug or a placebo pill, or no drug at all – and compared the treatments with each other. The results suggested DPP-4 inhibitor drugs were not associated with a reduced risk of death.

The findings also suggested SGLT-2 inhibitor drugs were linked to a 1 per cent decrease in absolute risk of death. The GLP-1 agonist medications were associated with a decrease in absolute risk of death by 0.6 per cent.

Further analysis revealed SGLT-2 inhibitor drugs were associated with a 21 per cent reduction in risk of dying specifically from a cardiovascular event such as a heart attack or stroke (absolute risk of 0.8 per cent), while GLP-1 agonist medication was associated with a 15 per cent drop in risk of death from a cardiovascular event (absolute risk reduction of 0.5 per cent). Further research also suggested that SGLT-2 inhibitor drugs were associated with significant reductions in risk of heart failure compared with both the other treatments.

There was no reduction in risk of death from a cardiovascular event for the drugs DPP-4 inhibitors.

Dr Zheng explained that the reasons behind the apparent reduced effectiveness of DPP-4 inhibitors is unclear, though it may be they are simply less powerful than the other two types of medication.

However, he cautioned that further work is now needed to confirm these findings, and stressed that anyone concerned about their drug regimen should consult their healthcare team. There was no evidence that any of the treatments caused harm.

The team also pointed out that because these drugs are relatively new, most trials only tracked patients for a few years – therefore more research is needed to look at the long-term risks and benefits of these drugs.

Source:

http://www.imperial.ac.uk/

Tagged with:

About author

Related Articles